{"id":"W4405009230","doi":"10.1016/s2352-3026(24)00319-3","title":"Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"Agios Pharmaceuticals","keywords":"Medicine; Placebo; Clinical trial; Internal medicine; Double blind; Physical therapy; Pediatrics; Intensive care medicine; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002007348,0.001539475,0.003920121,0.0003817909,0.0004085561,0.001154869,0.0009221309,0.002273204,0.004960931],"category_scores_gemma":[0.002479368,0.000612168,0.002335733,0.0003848805,0.001305336,0.001310178,0.0004208098,0.003389453,0.0008177754],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004784621,"about_ca_system_score_gemma":0.0005832332,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004178158,"about_ca_topic_score_gemma":0.0008724419,"domain_scores_codex":[0.9992513,0.0004140316,0.00004660601,0.0001182169,0.00006530695,0.000104624],"domain_scores_gemma":[0.9988349,0.0004746135,0.0003052318,0.00008808298,0.00006351105,0.0002338085],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9723159,0.001589038,0.0005429196,0.001399654,0.001759894,0.00005783581,0.00004107576,0.0001911696,0.002382879,0.00009256725,0.0008447041,0.01878241],"study_design_scores_gemma":[0.9507581,0.04381371,0.002751654,0.00008789326,0.001319283,0.00005563537,0.00001985993,0.000184817,0.0003624375,0.0001161806,0.0005111775,0.00001930777],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9600691,0.03227633,0.0007743238,0.00105031,0.0007809877,0.001461396,0.00102836,0.0002129667,0.002346272],"genre_scores_gemma":[0.9805729,0.01120958,0.001145569,0.001531113,0.0009111532,0.001548789,0.001095966,0.00003894353,0.001945873],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004960931,"threshold_uncertainty_score":0.01659596,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02336994305136065,"score_gpt":0.3126086637001989,"score_spread":0.2892387206488383,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}